Zybiraa 500mg Tablet USA | Bulk Oncology Exporter from India

Zybiraa 500mg Tablet: Advanced Hormonal Therapy for Metastatic Prostate Cancer

Are you searching for a reliable Zybiraa 500 mg tablet exporter from India? Ernest Oncology, a dedicated vertical of Ernest Pharmaceutical Pvt. Ltd., is a premier global bulk supplier and distributor of specialized oncology medications. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving medications reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Zybiraa 500mg?

Zybiraa 500 mg is a high-potency oral hormonal therapy containing the active pharmaceutical ingredient Abiraterone Acetate. It belongs to the class of medications known as androgen biosynthesis inhibitors.

Manufactured by Zydus Lifesciences Ltd., Zybiraa 500mg is precision-engineered to treat advanced prostate cancer that has progressed despite other hormonal treatments. For international B2B procurement, Zybiraa offers a world-class, cost-effective alternative to innovator brands, providing critical support for patients with advanced malignancies.

Primary Therapeutic Indications

Zybiraa 500 mg Tablet is clinically indicated for the management of:

1. Metastatic Castration-Resistant Prostate Cancer (mCRPC): For adult men whose prostate cancer has spread to other parts of the body and no longer responds to surgical or medical treatments that lower testosterone.

2. Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC): Used in combination with prednisone and androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.

Mechanism of Action: How Zybiraa 500mg Works

Zybiraa (Abiraterone Acetate) works by targeting the hormonal drivers of prostate cancer growth:

• CYP17 Enzyme Inhibition: It selectively and irreversibly inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase), which is required for androgen biosynthesis.

• Triple-Source Suppression: Unlike traditional treatments that only affect the testes, Zybiraa blocks testosterone production in three critical areas: the testes, the adrenal glands, and the prostate tumor tissue itself.

• Tumor Growth Arrest: By depriving the cancer cells of androgens (male hormones), Zybiraa stops the growth signals and effectively slows the progression of the disease.

Administration and Safety Guidelines

• Standard Dosage: The typical dose is 1,000 mg (two 500 mg tablets) taken orally once daily in combination with low-dose prednisone or prednisolone.

• Empty Stomach Requirement: Zybiraa must be taken on an empty stomach—at least one hour before or two hours after a meal. Taking it with food can significantly increase drug absorption to unsafe levels.

• Key Precautions:

• Monitoring: Regular monitoring of liver function (ALT/AST), blood pressure, and serum potassium levels is mandatory.

• Hepatotoxicity: Patients should report symptoms such as yellowing of the skin/eyes (jaundice) or dark urine immediately.

• Fluid Retention: This medication can cause hypertension and fluid retention (edema); patients with pre-existing heart conditions require close supervision.

• Contraindications: Zybiraa is strictly not for use in women or children.

Why Source Zybiraa 500 mg from Ernest Oncology?

• Direct Indian Exporter: Authentic supply from Zydus Lifesciences, ensuring 100% genuine products and competitive bulk pricing for international healthcare providers.

• Logistics Mastery: Deep expertise in navigating the specialized regulatory landscapes of the USA, UK, Australia, and South Africa.

• Bulk Supply Stability: We specialize in large-scale exports for oncology hospitals, specialty clinics, and regional distributors, ensuring consistent treatment access.

• Quality Assurance: Every shipment is accompanied by verified documentation and handled under strict GMP storage guidelines.